BioLine RX Stock

BioLine RX Gross Profit

Gross Profit of BioLine RX (BLRX.TA) as of Mar 15, 2026.

Gross Profit

0USD

Last updated: Mar 15, 2026

Gross Profit of BioLine RX is 2026 0 USD. Gross Profit of BioLine RX was 2025 0 USD. It decreases by % lower compared to the previous year.

The BioLine RX Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2005
0 base
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
6,460 base
Jan 1, 2010
7,738 base
Jan 1, 2011
0 base
Jan 1, 2012
0 base
Jan 1, 2013
0 base
Jan 1, 2014
0 base
Jan 1, 2015
0 base
Jan 1, 2016
0 base
Jan 1, 2017
0 base
Jan 1, 2018
0 base
Jan 1, 2019
0 base
YEARGROSS MARGIN (%)
2024 67,99
2023 23,08
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 77,38
2009 64,60
2008 -
2007 -
2006 -
2005 -

BioLine RX Revenue

BioLine RX Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
0 USD
-6.86 M USD
-6.31 M USD
Jan 1, 2006
0 USD
-13.06 M USD
-12.93 M USD
Jan 1, 2007
0 USD
-21.8 M USD
-14.48 M USD
Jan 1, 2008
0 USD
-33.31 M USD
-32.08 M USD
Jan 1, 2009
16.3 M USD
-16.14 M USD
-15.69 M USD
Jan 1, 2010
30.33 M USD
3.52 M USD
1.99 M USD
Jan 1, 2011
0 USD
-16.41 M USD
-14.04 M USD
Jan 1, 2012
0 USD
-21.19 M USD
-19.81 M USD
Jan 1, 2013
0 USD
-16.99 M USD
-17.04 M USD
Jan 1, 2014
0 USD
-17.16 M USD
-11.09 M USD
Jan 1, 2015
0 USD
-16.2 M USD
-14.4 M USD
Jan 1, 2016
0 USD
-16.51 M USD
-15.84 M USD
Jan 1, 2017
0 USD
-25.24 M USD
-24.35 M USD
Jan 1, 2018
0 USD
-25.61 M USD
-22.96 M USD
Jan 1, 2019
0 USD
-28.11 M USD
-25.45 M USD

BioLine RX Margins

BioLine RX stock margins

The BioLine RX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLine RX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLine RX.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
67.99 %
0 %
0 %
Jan 1, 2006
67.99 %
0 %
0 %
Jan 1, 2007
67.99 %
0 %
0 %
Jan 1, 2008
67.99 %
0 %
0 %
Jan 1, 2009
64.6 %
-99.02 %
-96.26 %
Jan 1, 2010
77.38 %
11.61 %
6.56 %
Jan 1, 2011
67.99 %
0 %
0 %
Jan 1, 2012
67.99 %
0 %
0 %
Jan 1, 2013
67.99 %
0 %
0 %
Jan 1, 2014
67.99 %
0 %
0 %
Jan 1, 2015
67.99 %
0 %
0 %
Jan 1, 2016
67.99 %
0 %
0 %
Jan 1, 2017
67.99 %
0 %
0 %
Jan 1, 2018
67.99 %
0 %
0 %
Jan 1, 2019
67.99 %
0 %
0 %

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.com.

Frequently Asked Questions about BioLine RX stock

On Eulerpool you can find the complete historical development of Gross Profit BioLine RX since 2006 – with annual values, charts, and detailed analysis.

Income Statement — BioLine RX

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

All Key Metrics — BioLine RX